Skip to content

Use of specific MRI sequences to diagnose various diseases of the brain and nerves

Quantitative Susceptibility mapping in the Diagnosis of neurodegenerative and demyelinating diseases - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106366
Enrollment
185
Registered
2026-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G308- Other Alzheimers disease Health Condition 2: G318- Other specified degenerative diseases of nervous system Health Condition 3: G20- Parkinsons disease Health Condition 4: G212- Secondary parkinsonism due to other external agents Health Condition 5: G231- Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] Health Condition 6: G26- Extrapyramidal and movement disorders in diseases classified elsewhere Health Condition 7: G360- Neuromyelitis optica [Devi

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

DrPiyush Goyal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a confirmed or clinically probable diagnosis of Neurodegenerative diseases (Alzheimer s, Parkinson s, Huntington s, Parkinson plus syndromes) Demyelinating diseases (Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders) Age matched healthy controls without neurological or psychiatric illness

Exclusion criteria

Exclusion criteria: History or presence of other major neurological disorders (e.g., tumors, stroke, epilepsy) Significant head injury or prior neurosurgery MRI scans with poor image quality or motion artefacts

Design outcomes

Primary

MeasureTime frame
Mean QSM values in disease-specific brain regions of interest (ROIs) Diagnostic accuracy (sensitivity, specificity, AUC) of QSM in detecting disease-specific changes Correlation between QSM values and clinical severity (where applicable)Timepoint: at the end of the study no specific time points

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Rajagopal K V

Kasturba Medical College, Manipal

rajagopal.kv@manipal.edu9448158901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026